NCBI Home Page NCBI Site Search page NCBI Guide that lists and describes the NCBI resources
Conserved domains on  [gi|20137480|sp|Q9H4A4|]
View 

RecName: Full=Aminopeptidase B; Short=AP-B; AltName: Full=Arginine aminopeptidase; AltName: Full=Arginyl aminopeptidase

Protein Classification

M1 family metallopeptidase( domain architecture ID 10176143)

M1 family metallopeptidase is a zinc-dependent metallopeptidase that functions as an aminopeptidase and contains an HEXXH motif as part of its active site; such as aminopeptidase B that selectively removes arginine and/or lysine residues from the N-terminus of peptide substrates

Graphical summary

 Zoom to residue level

show extra options »

Show site features     Horizontal zoom: ×

List of domain hits

Name Accession Description Interval E-value
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
24-484 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


:

Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 641.82  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  24 DVASASNFRAFELLHLHLDLRAEFGppgpgagSRGLSGTAVLDLRCLEPeGAAELRLDSHpCLEVTAAALRRerpgseep 103
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFD-------KKTISGSATLTLEVLQD-GADELVLDTR-DLDISSVTVNG-------- 63
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 104 pAEPVSFYTQPFS-HYGQALCVSFPQPCRAAERLQVLLTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPC 181
Cdd:cd09599  64 -GKELKFELGPRDpVLGSALTITLPSPLAKGDTFKVKIEYSTTPQaTALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPC 142
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 182 FDTPAVKYKYSALIEVPDGFTAVMSASTWEKR---GPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDA 258
Cdd:cd09599 143 QDTPSVKSTYSATVTVPKGLTALMSALRTGEKeeaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDA 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 259 AKEEYnGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTN 338
Cdd:cd09599 223 AAEEF-ADTEKFLKAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTN 301
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 339 ANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLrVKIEPGVDPDDTYNETPYEKGF 418
Cdd:cd09599 302 ANWEHFWLNEGFTVYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLL-VPDLKGVDPDDAFSSVPYEKGF 380
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 20137480 419 CFVSYLAHLVGdQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKkrvDIIPGFEFDRWLN 484
Cdd:cd09599 381 QFLYYLEQLGG-REVFDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKP---EILDKIDWDAWLY 442
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
530-644 5.68e-38

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


:

Pssm-ID: 462686  Cd Length: 112  Bit Score: 136.47  E-value: 5.68e-38
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   530 WKTYQLVYFLDKILQKSPLPPGNVKKLGDTYpSISNARNAELRLRWGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYH 609
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVY-KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|....*
gi 20137480   610 AMMggsEVAQTLAKETFASTASQLHSNVVNYVQQI 644
Cdd:pfam09127  80 ALN---KVDRDLAVETFEKNKDFYHPICRAMVEKD 111
 
Name Accession Description Interval E-value
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
24-484 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 641.82  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  24 DVASASNFRAFELLHLHLDLRAEFGppgpgagSRGLSGTAVLDLRCLEPeGAAELRLDSHpCLEVTAAALRRerpgseep 103
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFD-------KKTISGSATLTLEVLQD-GADELVLDTR-DLDISSVTVNG-------- 63
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 104 pAEPVSFYTQPFS-HYGQALCVSFPQPCRAAERLQVLLTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPC 181
Cdd:cd09599  64 -GKELKFELGPRDpVLGSALTITLPSPLAKGDTFKVKIEYSTTPQaTALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPC 142
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 182 FDTPAVKYKYSALIEVPDGFTAVMSASTWEKR---GPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDA 258
Cdd:cd09599 143 QDTPSVKSTYSATVTVPKGLTALMSALRTGEKeeaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDA 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 259 AKEEYnGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTN 338
Cdd:cd09599 223 AAEEF-ADTEKFLKAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTN 301
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 339 ANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLrVKIEPGVDPDDTYNETPYEKGF 418
Cdd:cd09599 302 ANWEHFWLNEGFTVYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLL-VPDLKGVDPDDAFSSVPYEKGF 380
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 20137480 419 CFVSYLAHLVGdQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKkrvDIIPGFEFDRWLN 484
Cdd:cd09599 381 QFLYYLEQLGG-REVFDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKP---EILDKIDWDAWLY 442
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
24-634 2.84e-174

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 509.32  E-value: 2.84e-174
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480    24 DVASASNFRAFELLHLHLDLRAEFGppgpgagSRGLSGTAVLDLRCLEPeGAAELRLDSHPcLEVTAAALRrerpgseep 103
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFT-------KRKLSGSVTFTLKSLTD-NLNKLVLDTSY-LDIQKVTIN--------- 62
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   104 pAEPVSFY-TQPFSHYGQALCVSFPQPCRAAERLQVLLTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPC 181
Cdd:TIGR02411  63 -GLPADFAiGERKEPLGSPLTISLPIATSKNDEFVLNISFSTTPKcTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPC 141
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   182 FDTPAVKYKYSALIEVPdgFTAVMSA--STWEKRGPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDAA 259
Cdd:TIGR02411 142 QDTPSVKSTYTAEVESP--LPVLMSGirDGETSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKC 219
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   260 KEEYNGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNA 339
Cdd:TIGR02411 220 QYEFENDTEKFIKTAEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNC 299
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   340 NWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLRVKIEPGvDPDDTYNETPYEKGFC 419
Cdd:TIGR02411 300 SWEHFWLNEGWTVYLERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFN 378
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   420 FVSYLAHLVGDQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKkrVDIIPGFEFDRWLNTPGWPPYLPDLSPgd 499
Cdd:TIGR02411 379 FLFYLEQLLGGPAEFDPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKK--VDKLDAVDWETWLYSPGMPPVKPNFDT-- 454
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   500 SLMKPAEELAQLW--AAEELDMKAIEAVAISPWKTYQLVYFLDKILQKS---PLPPGNVKKLGDTYPsISNARNAELRLR 574
Cdd:TIGR02411 455 TLADECYALADRWvdAAKADDLSSFNAKDIKDFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYN-FAASKNAEVRFR 533
                         570       580       590       600       610       620
                  ....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   575 WGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYHAMmgGSEVAQTLAKETFASTASQLH 634
Cdd:TIGR02411 534 WFRLAIQAKLEDEYPLLADWLGTVGRMKFVRPGYRLL--NAFVDRDLAIRTFEKFKDSYH 591
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
32-496 4.08e-83

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 273.44  E-value: 4.08e-83
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  32 RAFELLHLHLDLRaefgppgPGAGSRGLSGTAVLDLRCLEPeGAAELRLDSHPcLEVTAAALRRErpgseeppaepvsfy 111
Cdd:COG0308  13 PGYDVTHYDLDLD-------LDPATTRLSGTATITFTATEA-PLDSLVLDLKG-LEVTSVTVDGK--------------- 68
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 112 TQPFSHYGQALCVSFPQPCRAAERLQVLLTYRV-----GEGpgvcwLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPA 186
Cdd:COG0308  69 PLDFTRDGERLTITLPKPLAPGETFTLEIEYSGkpsngGEG-----LYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPD 143
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 187 VKYKYSALIEVPDGFTAVMSA---STWEKRGPNKFF-FQMCQPIPSYLIALAIGDLVSAEVGPRS----RVWAEPCLIDA 258
Cdd:COG0308 144 DKATFTLTVTVPAGWVAVSNGnlvSETELGDGRTTWhWADTQPIPTYLFALAAGDYAVVEDTFASgvplRVYVRPGLADK 223
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 259 AKEEYnGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGDR-------SLADVIIHEISHS 330
Cdd:COG0308 224 AKEAF-ESTKRMLDFFEELFGvPYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADETatdadyeRRESVIAHELAHQ 301
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 331 WFGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAytclEAATGRALLRQHMDITGEENPlNKLRVKIEPGVDPDDTYN 410
Cdd:COG0308 302 WFGNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKD----AADRIFVGALRSYAFAEDAGP-NAHPIRPDDYPEIENFFD 376
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 411 ETPYEKGFCFVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDfYLEyfpelKKKRVDIipGFEFDRWLNTPGWPP 490
Cdd:COG0308 377 GIVYEKGALVLHMLRTLLGD-EAFRAGLRLYFARHAGGNATTEDFLA-ALE-----EASGRDL--SAFFDQWLYQAGLPT 447

                ....*.
gi 20137480 491 YLPDLS 496
Cdd:COG0308 448 LEVEYE 453
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
262-482 1.63e-65

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 214.46  E-value: 1.63e-65
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   262 EYNGVIEEFLATGEKLFGPYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGD---------RSLADVIIHEISHSWF 332
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   333 GNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNklrVKIEPGVDPDDTYNET 412
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPIT---QNVNDPSEIDDIFDAI 157
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   413 PYEKGFCFVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDFYLEYfpeLKKKRVDIIpgfeFDRW 482
Cdd:pfam01433 158 PYEKGASVLRMLETLLGE-EVFQKGLRSYLKKFQYGNATTEDLWDALSEA---SGPLDVDSF----MDTW 219
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
530-644 5.68e-38

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 136.47  E-value: 5.68e-38
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   530 WKTYQLVYFLDKILQKSPLPPGNVKKLGDTYpSISNARNAELRLRWGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYH 609
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVY-KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|....*
gi 20137480   610 AMMggsEVAQTLAKETFASTASQLHSNVVNYVQQI 644
Cdd:pfam09127  80 ALN---KVDRDLAVETFEKNKDFYHPICRAMVEKD 111
 
Name Accession Description Interval E-value
M1_LTA4H cd09599
Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents ...
24-484 0e+00

Peptidase M1 family including Leukotriene A4 hydrolase catalytic domain; This model represents the N-terminal catalytic domain of leukotriene A4 hydrolase (LTA4H; E.C. 3.3.2.6) and the close homolog cold-active aminopeptidase (Colwellia psychrerythraea-type peptidase; ColAP), both members of the aminopeptidase M1 family. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase is poorly understood while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals. It accepts a variety of substrates, including some opioid, di- and tripeptides, as well as chromogenic aminoacyl-p-nitroanilide derivatives. The aminopeptidase activity of LTA4H is possibly involved in the processing of peptides related to inflammation and host defense. Kinetic analysis shows that LTA4H hydrolyzes arginyl tripeptides with high efficiency and specificity, indicating its function as an arginyl aminopeptidase. Thermodynamic characterization using different biophysical methods shows that structurally distinct inhibitors of the LTA4H occupy different regions of the binding site; while some (RB202, ARM1 and SC57461A) bind to the hydrophobic hydrolase side, both bestatin and captopril are located at the hydrophilic peptidase side. LTB4H overexpression is associated with different pathological conditions and diseases such as cystic fibrosis, coronary heart disease, sepsis, shock, connective tissue disease, and chronic obstructive pulmonary disease. It is also overexpressed in certain human cancers, and has been identified as a functionally important target for mediating anticancer properties of resveratrol, a well-known red wine polyphenolic compound with cancer chemopreventive activity.


Pssm-ID: 341062 [Multi-domain]  Cd Length: 442  Bit Score: 641.82  E-value: 0e+00
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  24 DVASASNFRAFELLHLHLDLRAEFGppgpgagSRGLSGTAVLDLRCLEPeGAAELRLDSHpCLEVTAAALRRerpgseep 103
Cdd:cd09599   1 DPSSFSNYDEVRTTHLDLDLTVDFD-------KKTISGSATLTLEVLQD-GADELVLDTR-DLDISSVTVNG-------- 63
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 104 pAEPVSFYTQPFS-HYGQALCVSFPQPCRAAERLQVLLTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPC 181
Cdd:cd09599  64 -GKELKFELGPRDpVLGSALTITLPSPLAKGDTFKVKIEYSTTPQaTALQWLTPEQTAGKKHPYLFTQCQAIHARSLFPC 142
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 182 FDTPAVKYKYSALIEVPDGFTAVMSASTWEKR---GPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDA 258
Cdd:cd09599 143 QDTPSVKSTYSATVTVPKGLTALMSALRTGEKeeaGTGTYTFEQPVPIPSYLIAIAVGDLESREIGPRSGVWAEPSVVDA 222
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 259 AKEEYnGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTN 338
Cdd:cd09599 223 AAEEF-ADTEKFLKAAEKLYGPYVWGRYDLLVLPPSFPYGGMENPCLTFATPTLIAGDRSLVDVIAHEIAHSWSGNLVTN 301
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 339 ANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLrVKIEPGVDPDDTYNETPYEKGF 418
Cdd:cd09599 302 ANWEHFWLNEGFTVYLERRILERLYGEEYRQFEAILGWKDLQESIKEFGEDPPYTLL-VPDLKGVDPDDAFSSVPYEKGF 380
                       410       420       430       440       450       460
                ....*....|....*....|....*....|....*....|....*....|....*....|....*.
gi 20137480 419 CFVSYLAHLVGdQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKkrvDIIPGFEFDRWLN 484
Cdd:cd09599 381 QFLYYLEQLGG-REVFDPFLRAYFKKFAFQSIDTEDFKDFLLEYFAEDKP---EILDKIDWDAWLY 442
leuko_A4_hydro TIGR02411
leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive ...
24-634 2.84e-174

leukotriene A-4 hydrolase/aminopeptidase; Members of this family represent a distinctive subset within the zinc metallopeptidase family M1 (pfam01433). The majority of the members of pfam01433 are aminopeptidases, but the sequences in this family for which the function is known are leukotriene A-4 hydrolase. A dual epoxide hydrolase and aminopeptidase activity at the same active site is indicated. The physiological substrate for aminopeptidase activity is not known.


Pssm-ID: 274120 [Multi-domain]  Cd Length: 602  Bit Score: 509.32  E-value: 2.84e-174
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480    24 DVASASNFRAFELLHLHLDLRAEFGppgpgagSRGLSGTAVLDLRCLEPeGAAELRLDSHPcLEVTAAALRrerpgseep 103
Cdd:TIGR02411   1 DPSSLSNYKDFRTSHTDLNLSVDFT-------KRKLSGSVTFTLKSLTD-NLNKLVLDTSY-LDIQKVTIN--------- 62
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   104 pAEPVSFY-TQPFSHYGQALCVSFPQPCRAAERLQVLLTYRVGEG-PGVCWLAPEQTAGKKKPFVYTQGQAVLNRAFFPC 181
Cdd:TIGR02411  63 -GLPADFAiGERKEPLGSPLTISLPIATSKNDEFVLNISFSTTPKcTALQWLNPEQTSGKKHPYLFSQCQAIHARSLFPC 141
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   182 FDTPAVKYKYSALIEVPdgFTAVMSA--STWEKRGPNKFFFQMCQPIPSYLIALAIGDLVSAEVGPRSRVWAEPCLIDAA 259
Cdd:TIGR02411 142 QDTPSVKSTYTAEVESP--LPVLMSGirDGETSNDPGKYLFKQKVPIPAYLIAIASGDLASAPIGPRSTVYSEPEQLEKC 219
                         250       260       270       280       290       300       310       320
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   260 KEEYNGVIEEFLATGEKLFGPYVWGRYDLLFMPPSFPFGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNA 339
Cdd:TIGR02411 220 QYEFENDTEKFIKTAEDLIFPYEWGQYDLLVLPPSFPYGGMENPNLTFATPTLIAGDRSNVDVIAHELAHSWSGNLVTNC 299
                         330       340       350       360       370       380       390       400
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   340 NWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLRVKIEPGvDPDDTYNETPYEKGFC 419
Cdd:TIGR02411 300 SWEHFWLNEGWTVYLERRIIGRLYGEKTRHFSALIGWGDLQESVKTLGETPEFTKLVVDLKDN-DPDDAFSSVPYEKGFN 378
                         410       420       430       440       450       460       470       480
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   420 FVSYLAHLVGDQDQFDSFLKAYVHEFKFRSILADDFLDFYLEYFPELKKkrVDIIPGFEFDRWLNTPGWPPYLPDLSPgd 499
Cdd:TIGR02411 379 FLFYLEQLLGGPAEFDPFLRHYFKKFAYKSLDTYQFKDALYEYFKDKKK--VDKLDAVDWETWLYSPGMPPVKPNFDT-- 454
                         490       500       510       520       530       540       550       560
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   500 SLMKPAEELAQLW--AAEELDMKAIEAVAISPWKTYQLVYFLDKILQKS---PLPPGNVKKLGDTYPsISNARNAELRLR 574
Cdd:TIGR02411 455 TLADECYALADRWvdAAKADDLSSFNAKDIKDFSSHQLVLFLETLTERGgdwALPEGHIKRLGDIYN-FAASKNAEVRFR 533
                         570       580       590       600       610       620
                  ....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   575 WGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYHAMmgGSEVAQTLAKETFASTASQLH 634
Cdd:TIGR02411 534 WFRLAIQAKLEDEYPLLADWLGTVGRMKFVRPGYRLL--NAFVDRDLAIRTFEKFKDSYH 591
M1 cd09595
Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 ...
38-458 2.30e-83

Peptidase M1 family includes the catalytic domains of aminopeptidase N and leukotriene A4 hydrolase; The model represents the catalytic domains of M1 peptidase family members including aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). All peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile upon activation during catalysis. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. APN expression is dysregulated in many inflammatory diseases and is enhanced in numerous tumor cells, making it a lead target in the development of anti-cancer and anti-inflammatory drugs. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity. The two activities occupy different, but overlapping sites. The activity and physiological relevance of the aminopeptidase in LTA4H is as yet unknown, while the epoxide hydrolase converts leukotriene A4 (LTA4) into leukotriene B4 (LTB4), a potent chemotaxin that is fundamental to the inflammatory response of mammals.


Pssm-ID: 341058 [Multi-domain]  Cd Length: 413  Bit Score: 268.54  E-value: 2.30e-83
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  38 HLHLDLRAEFGppgpgagSRGLSGTAVLDLRclEPEGAAELRLDSH--PCLEVTAAALRRERPGSEEPPAEPVsfytqpf 115
Cdd:cd09595   2 HYDLDLDVDFT-------TKTLNGTETLTVD--ASQVGRELVLDLVglTIHSVSVNGAAVDFGEREHYDGEKL------- 65
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 116 shygqALCVSFPQPcraaERLQVLLTYRVGE---GPGVCWlapEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPAVKYKYS 192
Cdd:cd09595  66 -----TIPGPKPPG----QTFTVRISFEAKPsknLLGWLW---EQTAGKEKPYLFTQFEATHARRIFPCIDHPAVKATFT 133
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 193 ALIEVPDGFT-AVMSASTWEKRGPNK---FFFQMCQPIPSYLIALAIGDLVSAEVGPRSR------VWAEPCLIDAAKEE 262
Cdd:cd09595 134 VTITTPKKDLlASNGALVGEETGANGrktYRFEDTPPIPTYLVAVVVGDLEFKYVTVKSQprvglsVYSEPLQVDQAQYA 213
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 263 YnGVIEEFLATGEKLFG-PYVWGRYDLLfMPPSFPFGGMENPCLTFVTPCLLA-------GDRSLADVIIHEISHSWFGN 334
Cdd:cd09595 214 F-DATRAALAWFEDYFGgPYPLPKYDLL-AVPDFNSGAMENPGLITFRTTYLLrskvtdtGARSIENVIAHELAHQWFGN 291
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 335 LVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLnklrVKIEPGVDPDDTYNETPY 414
Cdd:cd09595 292 LVTMRWWNDLWLNEGFAVYYENRIMDATFGTSSRHLDQLSGSSDLNTEQLLEDSSPTS----TPVRSPADPDVAYDGVTY 367
                       410       420       430       440
                ....*....|....*....|....*....|....*....|....
gi 20137480 415 EKGFCFVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDF 458
Cdd:cd09595 368 AKGALVLRMLEELVGE-EAFDKGVQAYFNRHKFKNATTDDFIDA 410
PepN COG0308
Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];
32-496 4.08e-83

Aminopeptidase N, contains DUF3458 domain [Amino acid transport and metabolism];


Pssm-ID: 440077 [Multi-domain]  Cd Length: 609  Bit Score: 273.44  E-value: 4.08e-83
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  32 RAFELLHLHLDLRaefgppgPGAGSRGLSGTAVLDLRCLEPeGAAELRLDSHPcLEVTAAALRRErpgseeppaepvsfy 111
Cdd:COG0308  13 PGYDVTHYDLDLD-------LDPATTRLSGTATITFTATEA-PLDSLVLDLKG-LEVTSVTVDGK--------------- 68
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 112 TQPFSHYGQALCVSFPQPCRAAERLQVLLTYRV-----GEGpgvcwLAPEQTAGKKKPFVYTQGQAVLNRAFFPCFDTPA 186
Cdd:COG0308  69 PLDFTRDGERLTITLPKPLAPGETFTLEIEYSGkpsngGEG-----LYRSGDPPDGPPYLYTQCEPEGARRWFPCFDHPD 143
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 187 VKYKYSALIEVPDGFTAVMSA---STWEKRGPNKFF-FQMCQPIPSYLIALAIGDLVSAEVGPRS----RVWAEPCLIDA 258
Cdd:COG0308 144 DKATFTLTVTVPAGWVAVSNGnlvSETELGDGRTTWhWADTQPIPTYLFALAAGDYAVVEDTFASgvplRVYVRPGLADK 223
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 259 AKEEYnGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGDR-------SLADVIIHEISHS 330
Cdd:COG0308 224 AKEAF-ESTKRMLDFFEELFGvPYPFDKYDQVAVP-DFNFGAMENQGLVTFGEKVLADETatdadyeRRESVIAHELAHQ 301
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 331 WFGNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAytclEAATGRALLRQHMDITGEENPlNKLRVKIEPGVDPDDTYN 410
Cdd:COG0308 302 WFGNLVTCADWDDLWLNEGFATYMEQLFSEDLYGKD----AADRIFVGALRSYAFAEDAGP-NAHPIRPDDYPEIENFFD 376
                       410       420       430       440       450       460       470       480
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 411 ETPYEKGFCFVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDfYLEyfpelKKKRVDIipGFEFDRWLNTPGWPP 490
Cdd:COG0308 377 GIVYEKGALVLHMLRTLLGD-EAFRAGLRLYFARHAGGNATTEDFLA-ALE-----EASGRDL--SAFFDQWLYQAGLPT 447

                ....*.
gi 20137480 491 YLPDLS 496
Cdd:COG0308 448 LEVEYE 453
Peptidase_M1 pfam01433
Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ ...
262-482 1.63e-65

Peptidase family M1 domain; Members of this family are aminopeptidases. The members differ widely in specificity, hydrolysing acidic, basic or neutral N-terminal residues. This family includes leukotriene-A4 hydrolase, this enzyme also has an aminopeptidase activity.


Pssm-ID: 426262 [Multi-domain]  Cd Length: 219  Bit Score: 214.46  E-value: 1.63e-65
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   262 EYNGVIEEFLATGEKLFGPYVWGRYDLLFMPpSFPFGGMENPCLTFVTPCLLAGD---------RSLADVIIHEISHSWF 332
Cdd:pfam01433   2 ALEITVKLLEFYEDYFNIPYPLPKYDLVALP-DFSAGAMENWGLITYRETLLLYDpgnsstsdkQRVASVIAHELAHQWF 80
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   333 GNLVTNANWGEFWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNklrVKIEPGVDPDDTYNET 412
Cdd:pfam01433  81 GNLVTMKWWDDLWLNEGFATYMEYLGTDALFPEWNIWEQFLLDEVQNAMARDALDSSHPIT---QNVNDPSEIDDIFDAI 157
                         170       180       190       200       210       220       230
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   413 PYEKGFCFVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDFYLEYfpeLKKKRVDIIpgfeFDRW 482
Cdd:pfam01433 158 PYEKGASVLRMLETLLGE-EVFQKGLRSYLKKFQYGNATTEDLWDALSEA---SGPLDVDSF----MDTW 219
M1_APN_like cd09603
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly ...
34-458 1.85e-62

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains mostly bacterial and some archaeal M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341066 [Multi-domain]  Cd Length: 410  Bit Score: 212.83  E-value: 1.85e-62
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480  34 FELLHLHLDLRAEFGppgpgagSRGLSGTAVLDLRCLEPegAAELRLDSHPcLEVTAAALRRErpgseeppaePVSFYTq 113
Cdd:cd09603   1 YDVLHYDLDLDYDPA-------TKSLSGTATITFRATQD--LDSLQLDLVG-LTVSSVTVDGV----------PAAFFT- 59
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 114 pfsHYGQALCVSFPQPCRAAERLQVLLTY----RVGEGPGvcWLAPEQTAGKkkPFVYTQGQAVLNRAFFPCFDTPAVKY 189
Cdd:cd09603  60 ---HDGDKLVITLPRPLAAGETFTVTVRYsgkpRPAGYPP--GDGGGWEEGD--DGVWTAGQPEGASTWFPCNDHPDDKA 132
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 190 KYSALIEVPDGFTAV---MSASTWEKRGPNK-FFFQMCQPIPSYLIALAIGDLVSAEVGPRSRV----WAEPCLIDAAKE 261
Cdd:cd09603 133 TYDITVTVPAGLTVVsngRLVSTTTNGGGTTtWHWKMDYPIATYLVTLAVGRYAVVEDGSGGGIplryYVPPGDAAKAKA 212
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 262 EYNGVIE--EFLatgEKLFGPYVWGRYDLLFMPPSFpfGGMENPCLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTNA 339
Cdd:cd09603 213 SFARTPEmlDFF---EELFGPYPFEKYGQVVVPDLG--GGMEHQTATTYGNNFLNGDRGSERLIAHELAHQWFGDSVTCA 287
                       330       340       350       360       370       380       390       400
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 340 NWGEFWLNEGFTMYAQrristilfgAAYTclEAATGRALLRQHMDitGEENPLNKLRVKIEPGVDPDDTYNETPYEKGFC 419
Cdd:cd09603 288 DWADIWLNEGFATYAE---------WLWS--EHKGGADAYRAYLA--GQRQDYLNADPGPGRPPDPDDLFDRDVYQKGAL 354
                       410       420       430
                ....*....|....*....|....*....|....*....
gi 20137480 420 FVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDF 458
Cdd:cd09603 355 VLHMLRNLLGD-EAFFAALRAYLARYAHGNVTTEDFIAA 392
M1_APN-Q_like cd09601
Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), ...
160-484 2.18e-38

Peptidase M1 aminopeptidase N catalytic domain family which includes aminopeptidase N (APN), aminopeptidase Q (APQ), tricorn interacting factor F3, and endoplasmic reticulum aminopeptidase 1 (ERAP1); This M1 peptidase family includes eukaryotic and bacterial members: the catalytic domains of aminopeptidase N (APN), aminopeptidase Q (APQ, laeverin), endoplasmic reticulum aminopeptidase 1 (ERAP1) as well as tricorn interacting factor F3. Aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease, preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is considered a marker of differentiation since it is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. ERAP1, also known as endoplasmic reticulum aminopeptidase associated with antigen processing (ERAAP), adipocyte derived leucine aminopeptidase (A-LAP), or aminopeptidase regulating tumor necrosis factor receptor I (THFRI) shedding (ARTS-1), associates with the closely related ER aminopeptidase ERAP2, for the final trimming of peptides within the ER for presentation by MHC class I molecules. ERAP1 is associated with ankylosing spondylitis (AS), an inflammatory arthritis that predominantly affects the spine. ERAP1 also aids in the shedding of membrane-bound cytokine receptors. The tricorn interacting factor F3, together with factors F1 and F2, degrades the tricorn protease products, producing free amino acids, thus completing the proteasomal degradation pathway. F3 is homologous to F2, but not F1, and shows a strong preference for glutamate in the P1' position. APQ, also known as laeverin, is specifically expressed in human embryo-derived extravillous trophoblasts (EVTs) that invade the uterus during early placentation. It cleaves the N-terminal amino acid of various peptides such as angiotensin III, endokinin C, and kisspeptin-10, all expressed in the placenta in large quantities. APN is a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs are also putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341064 [Multi-domain]  Cd Length: 442  Bit Score: 147.73  E-value: 2.18e-38
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 160 GKKKPFVYTQGQAVLNRAFFPCFDTPAVKYKYSALIEVPDGFTAV--MSA--STWEKRGPNKFFFQMCQPIPSYLIALAI 235
Cdd:cd09601 110 GETRYLAATQFEPTDARRAFPCFDEPAFKATFDITITHPKGYTALsnMPPveSTELEDGWKTTTFETTPPMSTYLVAFVV 189
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 236 GDLVSAEV----GPRSRVWAEPCLIDAAKE--EYNGVIEEFLatgEKLFG-PYVwgrydllfMP-------PSFPFGGME 301
Cdd:cd09601 190 GDFEYIESttksGVPVRVYARPGKIEQGDFalEVAPKILDFY---EDYFGiPYP--------LPkldlvaiPDFAAGAME 258
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 302 NP-CLTFVTPCLLAGD--------RSLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRristilFGAAYTCLE- 371
Cdd:cd09601 259 NWgLITYRETALLYDPktssasdkQRVAEVIAHELAHQWFGNLVTMKWWDDLWLNEGFATYMEY------LAVDKLFPEw 332
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 372 --------AATGRALlrqHMDITGEENPlnkLRVKIEPGVDPDDTYNETPYEKGFCFVSYLAHLVGDqDQFDSFLKAYVH 443
Cdd:cd09601 333 nmwdqfvvDELQSAL---ELDSLASSHP---IEVPVESPSEISEIFDAISYSKGASVLRMLENFLGE-EVFRKGLRKYLK 405
                       330       340       350       360
                ....*....|....*....|....*....|....*....|.
gi 20137480 444 EFKFRSILADDFLDFYLEYFPELKKKRVDIIpgfeFDRWLN 484
Cdd:cd09601 406 KHAYGNATTDDLWEALQEASGESKPLDVKEI----MDSWTL 442
Leuk-A4-hydro_C pfam09127
Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of ...
530-644 5.68e-38

Leukotriene A4 hydrolase, C-terminal; Members of this family adopt a structure consisting of two layers of parallel alpha-helices, five in the inner layer and four in the outer, arranged in an antiparallel manner, with perpendicular loops containing short helical segments on top. They are required for the formation of a deep cleft harbouring the catalytic Zn2+ site in Leukotriene A4 hydrolase.


Pssm-ID: 462686  Cd Length: 112  Bit Score: 136.47  E-value: 5.68e-38
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   530 WKTYQLVYFLDKILQKSPLPPGNVKKLGDTYpSISNARNAELRLRWGQIVLKNDHQEDFWKVKEFLHNQGKQKYTLPLYH 609
Cdd:pfam09127   1 WSSNQKVVFLERLLEFSPLSPEQLKALDEVY-KLSESKNAEIRFRWLRLALKAKYEPAYPEVAEFLGEVGRMKFVRPLYR 79
                          90       100       110
                  ....*....|....*....|....*....|....*
gi 20137480   610 AMMggsEVAQTLAKETFASTASQLHSNVVNYVQQI 644
Cdd:pfam09127  80 ALN---KVDRDLAVETFEKNKDFYHPICRAMVEKD 111
M1_APN cd09602
Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the ...
162-457 3.88e-31

Peptidase M1 family including aminopeptidase N catalytic domain; This model represents the catalytic domain of bacterial and eukaryotic aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341065 [Multi-domain]  Cd Length: 440  Bit Score: 126.48  E-value: 3.88e-31
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 162 KKPFVYTQGqaVLNRA--FFPCFDTPAVKYKYSALIEVPDGFTAV---MSASTWEKRGPNKFFFQMCQPIPSYLIALAIG 236
Cdd:cd09602 114 GETYLYTLF--EPDDArrVFPCFDQPDLKATFTLTVTAPADWTVIsngPETSTEEAGGRKRWRFAETPPLSTYLFAFVAG 191
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 237 DLVSAEVGPRS---RVWAEPCLIDAAK--EEYNGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENP-CLTF-- 307
Cdd:cd09602 192 PYHRVEDEHDGiplGLYCRESLAEYERdaDEIFEVTKQGLDFYEDYFGiPYPFGKYDQVFVP-EFNFGAMENPgAVTFre 270
                       170       180       190       200       210       220       230       240
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 308 -------VTPCLLAGdrsLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYaqrristilfgAAYTCLEAATG----- 375
Cdd:cd09602 271 sylfreePTRAQRLR---RANTILHEMAHMWFGDLVTMKWWDDLWLNESFADF-----------MAAKALAEATPftdaw 336
                       250       260       270       280       290       300       310       320
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 376 -RALLRQ-----HMDITGEENPlnklrvkIEPgvDPDDT------YNETPYEKGFCFVSYLAHLVGDqDQFDSFLKAYVH 443
Cdd:cd09602 337 lTFLLRRkpwayRADQLPTTHP-------IAQ--DVPDLeaagsnFDGITYAKGASVLKQLVALVGE-EAFRAGLREYFK 406
                       330
                ....*....|....
gi 20137480 444 EFKFRSILADDFLD 457
Cdd:cd09602 407 KHAYGNATLDDLIA 420
pepN_strep_liv TIGR02412
aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the ...
163-457 7.21e-28

aminopeptidase N, Streptomyces lividans type; This family is a subset of the members of the zinc metallopeptidase family M1 (pfam01433), with a single member characterized in Streptomyces lividans 66 and designated aminopeptidase N. The spectrum of activity may differ somewhat from the aminopeptidase N clade of E. coli and most other Proteobacteria, well separated phylogenetically within the M1 family. The M1 family also includes leukotriene A-4 hydrolase/aminopeptidase (with a bifunctional active site).


Pssm-ID: 274121 [Multi-domain]  Cd Length: 831  Bit Score: 119.51  E-value: 7.21e-28
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   163 KPFVYTQGQAVLNRAFFPCFDTPAVKYKYSALIEVPDGFTaVMSASTWE----KRGPNKFFFQMCQPIPSYLIALAIGDL 238
Cdd:TIGR02412 117 EVYLYTQFEPADARRVFAVFDQPDLKANFKFSVKAPEDWT-VISNSRETdvtpEPADRRWEFPETPKLSTYLTAVAAGPY 195
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   239 VSAEVGPRS---RVWAEPCL---IDAakEEYNGVIEEFLATGEKLFG-PYVWGRYDLLFMPpSFPFGGMENP-CLTF--- 307
Cdd:TIGR02412 196 HSVQDESRSyplGIYARRSLaqyLDA--DAIFTITRQGLAFFHRKFGyPYPFKKYDQIFVP-EFNAGAMENAgCVTFaen 272
                         170       180       190       200       210       220       230       240
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   308 ------VTPCLLAGdrsLADVIIHEISHSWFGNLVTNANWGEFWLNEGFTMYAQRRISTilfgAAYTCLEAATGRALLRQ 381
Cdd:TIGR02412 273 flhraeATRAEKEN---RAGVILHEMAHMWFGDLVTMRWWNDLWLNESFAEYMGTLASA----EATEYTDAWTTFAAQGK 345
                         250       260       270       280       290       300       310
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*..
gi 20137480   382 HMDITGEENPL-NKLRVKIEPGVDPDDTYNETPYEKGFCFVSYLAHLVGDQDqFDSFLKAYVHEFKFRSILADDFLD 457
Cdd:TIGR02412 346 QWAYEADQLPTtHPIVADVADLADALSNFDGITYAKGASVLKQLVAWVGEEA-FFAGVNAYFKRHAFGNATLDDLID 421
M1_APN_like cd09604
Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains ...
244-458 1.67e-23

Peptidase M1 family similar to aminopeptidase N catalytic domain; This family contains bacterial M1 peptidases with smilarity to the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341067 [Multi-domain]  Cd Length: 440  Bit Score: 103.89  E-value: 1.67e-23
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 244 GPRSRVWAEPCLIDAAkEEYNGVIEEFLATGEKLFGPYVWGRYDLLFMPpsFPFGGMENPCLTFVTPCLLAGDRSLADVI 323
Cdd:cd09604 221 GVTVNVYYLPENAEAA-ERALEYAKDALEFFSEKFGPYPYPELDVVQGP--FGGGGMEYPGLVFIGSRLYDPKRSLEGVV 297
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 324 IHEISHSWFGNLVTN--ANWGefWLNEGFTMYAQRRISTILFGAAYTCLEAATGRALLRQHMDITGEENPLNKLrvkiep 401
Cdd:cd09604 298 VHEIAHQWFYGIVGNdeRREP--WLDEGLATYAESLYLEEKYGKEAADELLGRRYYRAYARGPGGPINLPLDTF------ 369
                       170       180       190       200       210
                ....*....|....*....|....*....|....*....|....*....|....*..
gi 20137480 402 gvDPDDTYNETPYEKGFCFVSYLAHLVGDqDQFDSFLKAYVHEFKFRSILADDFLDF 458
Cdd:cd09604 370 --PDGSYYSNAVYSKGALFLEELREELGD-EAFDKALREYYRRYKFKHPTPEDFFRT 423
GluZincin cd09594
Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, ...
274-353 1.59e-16

Gluzincin Peptidase family (thermolysin-like proteinases, TLPs) which includes peptidases M1, M2, M3, M4, M13, M32 and M36 (fungalysins); The Gluzincin family (thermolysin-like peptidases or TLPs) includes several zinc-dependent metallopeptidases such as M1, M2, M3, M4, M13, M32, M36 peptidases (MEROPS classification), which contain the HEXXH motif as part of their active site. Peptidases in this family bind a single catalytic zinc ion which is tetrahedrally co-ordinated by three amino acid ligands and a water molecule that forms the nucleophile on activation during catalysis. The M1 family includes aminopeptidase N (APN) and leukotriene A4 hydrolase (LTA4H). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and is present in a variety of human tissues and cell types. LTA4H is a bifunctional enzyme, possessing an aminopeptidase as well as an epoxide hydrolase activity such that the two activities occupy different, but overlapping sites. The M3_like peptidases include the M2_ACE, M3 or neurolysin-like family (subfamilies M3B_PepF and M3A) and M32_Taq peptidases. The M2 peptidase angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of decapeptide angiotensin I to the potent vasopressor octapeptide angiotensin II. ACE is a key component of the renin-angiotensin system that regulates blood pressure, thus ACE inhibitors are important for the treatment of hypertension. M3A includes thimet oligopeptidase (TOP; endopeptidase 3.4.24.15), neurolysin (3.4.24.16), and the mitochondrial intermediate peptidase; and M3B includes oligopeptidase F. The M32 family includes eukaryotic enzymes from protozoa Trypanosoma cruzi, a causative agent of Chagas' disease, and from Leishmania major, a parasite that causes leishmaniasis, making these enzymes attractive targets for drug development. The M4 family includes secreted protease thermolysin (EC 3.4.24.27), pseudolysin, aureolysin, and neutral protease as well as bacillolysin (EC 3.4.24.28) that degrade extracellular proteins and peptides for bacterial nutrition, especially prior to sporulation. Thermolysin is widely used as a nonspecific protease to obtain fragments for peptide sequencing as well as in production of the artificial sweetener aspartame. The M13 family includes neprilysin (EC 3.4.24.11) and endothelin-converting enzyme I (ECE-1, EC 3.4.24.71), which fulfill a broad range of physiological roles due to the greater variation in the S2' subsite allowing substrate specificity and are prime therapeutic targets for selective inhibition. The peptidase M36 fungalysin family includes endopeptidases from pathogenic fungi. Fungalysin hydrolyzes extracellular matrix proteins such as elastin and keratin. Aspergillus fumigatus causes the pulmonary disease aspergillosis by invading the lungs of immuno-compromised animals and secreting fungalysin that possibly breaks down proteinaceous structural barriers.


Pssm-ID: 341057 [Multi-domain]  Cd Length: 105  Bit Score: 75.60  E-value: 1.59e-16
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 274 GEKLFGPYVWGRYDLLFMPP---SFPFGGMENP-CLTFVTPCLLAGDRSLADVIIHEISHSWFGNLVTN-ANWGEFWLNE 348
Cdd:cd09594  16 GRTSFRYPVSPIYSLLVYPAyveVNAYNAMWIPsTNIFYGAGILDTLSGTIDVLAHELTHAFTGQFSNLmYSWSSGWLNE 95

                ....*
gi 20137480 349 GFTMY 353
Cdd:cd09594  96 GISDY 100
M1_APN cd09600
Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the ...
225-353 1.06e-13

Peptidase M1 family, including aminopeptidase N catalytic domain; This model represents the catalytic domain of aminopeptidase N (APN; CD13; alanyl aminopeptidase; EC 3.4.11.2), a type II integral membrane protease belonging to the M1 gluzincin family. It includes bacterial-type alanyl aminopeptidases as well as PfA-M1 aminopeptidase (Plasmodium falciparum-type). APN preferentially cleaves neutral amino acids from the N-terminus of oligopeptides and, in higher eukaryotes, is present in a variety of human tissues and cell types (leukocyte, fibroblast, endothelial and epithelial cells). APN expression is dysregulated in inflammatory diseases such as chronic pain, rheumatoid arthritis, multiple sclerosis, systemic sclerosis, systemic lupus erythematosus, polymyositis/dermatomyosytis and pulmonary sarcoidosis, and is enhanced in tumor cells such as melanoma, renal, prostate, pancreas, colon, gastric and thyroid cancers. It is predominantly expressed on stem cells and on cells of the granulocytic and monocytic lineages at distinct stages of differentiation, thus considered a marker of differentiation. Thus, APN inhibition may lead to the development of anti-cancer and anti-inflammatory drugs. APNs are also present in many pathogenic bacteria and represent potential drug targets. Some APNs have been used commercially, such as one from Lactococcus lactis used in the food industry. APN also serves as a receptor for coronaviruses, although the virus receptor interaction site seems to be distinct from the enzymatic site and aminopeptidase activity is not necessary for viral infection. APNs have also been extensively studied as putative Cry toxin receptors. Cry1 proteins are pore-forming toxins that bind to the midgut epithelial cell membrane of susceptible insect larvae, causing extensive damage. Several different toxins, including Cry1Aa, Cry1Ab, Cry1Ac, Cry1Ba, Cry1Ca and Cry1Fa, have been shown to bind to APNs; however, a direct role of APN in cytotoxicity has been yet to be firmly established.


Pssm-ID: 341063 [Multi-domain]  Cd Length: 434  Bit Score: 73.70  E-value: 1.06e-13
                        10        20        30        40        50        60        70        80
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 225 PIPSYLIALAIGDLVSAE--VGPRS------RVWAEP-----------CLIDAAK--EEyngvieeflatgeklfgpyVW 283
Cdd:cd09600 174 PKPSYLFALVAGDLGSVEdtFTTKSgrkvklRIYVEPgnedkchhameSLKKAMKwdEE-------------------RF 234
                        90       100       110       120       130       140       150       160
                ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480 284 GR-YDL-LFM---PPSFPFGGMENPCLT-FVTPCLLAGDRSLAD--------VIIHEISHSWFGNLVTNANWGEFWLNEG 349
Cdd:cd09600 235 GLeYDLdLFNivaVDDFNMGAMENKGLNiFNSKYVLADPETATDadyeriesVIAHEYFHNWTGNRVTCRDWFQLSLKEG 314

                ....
gi 20137480 350 FTMY 353
Cdd:cd09600 315 LTVF 318
Peptidase_M1_N pfam17900
Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from ...
37-230 6.92e-09

Peptidase M1 N-terminal domain; This domain is found at the N-terminus of aminopeptidases from the M1 family.


Pssm-ID: 465557 [Multi-domain]  Cd Length: 186  Bit Score: 55.81  E-value: 6.92e-09
                          10        20        30        40        50        60        70        80
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480    37 LHLHLDLRaefgppgpgagSRGLSGTAVLDLRCLEPEgaAELRLDSHPcLEVTAAALRRErPGSEEPPAEPVSFYTQpfs 116
Cdd:pfam17900   7 LDLKIDLK-----------NFTFSGSVTITLQLNNAT--NVIVLHASD-LTIRSISLSDE-VTSDGVPADFTEDQKD--- 68
                          90       100       110       120       130       140       150       160
                  ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
gi 20137480   117 hyGQALCVSFPQPCRAAERLQVLLTYRVgegpgvcWLAPEQTA---------GKKKPFVYTQGQAVLNRAFFPCFDTPAV 187
Cdd:pfam17900  69 --GEKLTIVLPETLNQTGPYTLEIEYSG-------ELNDSMTGfyrstytdnGEKKVLVTTQFEPTDARSAFPCFDEPSV 139
                         170       180       190       200
                  ....*....|....*....|....*....|....*....|....*..
gi 20137480   188 KYKYSALIEVPDGFTAV--MS--ASTWEKRGPNKFFFQMCQPIPSYL 230
Cdd:pfam17900 140 KATFTISIIHPKDYTALsnMPviASEPLENGWVITTFEQTPKMSTYL 186
 
Blast search parameters
Data Source: Precalculated data, version = cdd.v.3.21
Preset Options:Database: CDSEARCH/cdd   Low complexity filter: no  Composition Based Adjustment: yes   E-value threshold: 0.01

References:

  • Wang J et al. (2023), "The conserved domain database in 2023", Nucleic Acids Res.51(D)384-8.
  • Lu S et al. (2020), "The conserved domain database in 2020", Nucleic Acids Res.48(D)265-8.
  • Marchler-Bauer A et al. (2017), "CDD/SPARCLE: functional classification of proteins via subfamily domain architectures.", Nucleic Acids Res.45(D)200-3.
Help | Disclaimer | Write to the Help Desk
NCBI | NLM | NIH